Latest News
|
| 10-04-2013 | Phylogica Engages Financial Advisor |
| 23-03-2013 | Phylogica Granted Core Phylomer® Patent In Australia |
| 14-03-2013 | Shareholder Update March 2013 |
| 05-02-2013 | Collaboration to Commercialise Anti Inflammatory Phylomers |
| 31-01-2013 | Janssen Collaboration Extended |
Phylogica is a leading peptide drug discovery company that utilises proprietary Phylomer peptide libraries and screening methodologies to identify unique peptide drug candidates for its pharmaceutical and biotechnology partners.
Phylomer® libraries contain the world's largest and most structurally diverse array of natural peptides. These peptides, known as Phylome® peptides, are sourced from evolutionary diverse microbes and they represent a new class of biological therapeutics. Phylomer® peptides display exceptional structural stability, specificity and affinity thereby giving them the potential to address disease targets that are intractable to small molecules and other protein biologics including antibodies. Read more…